Business
ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th
PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani,

About this update from Ani Pharmaceuticals, Inc.
PRINCETON, N.J. , July 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani , President and Chief Executive Officer, will host 1x1 meetings at the Leerink Partners Therapeutics Forum : I&I and Metabolism on Tuesday, July 8, 2025 , in Boston, MA. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S. -based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com . Investor Relations: Lisa M. Wilson , In-Site Communications, Inc. T: 212-452-2793 E: [email protected] Source: ANI Pharmaceuticals, Inc. Source: ANI Pharmaceuticals, Inc.
View stock analysis, news, and events for Ani Pharmaceuticals, Inc.